With President Obama’s re-election, implementation of the Affordable Care Act (ACA) will move forward, full speed ahead, according to one industry expert.
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More